| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 460.30M | 500.60M | 470.40M | 444.70M | 367.30M | 318.50M |
| Gross Profit | 233.60M | 258.80M | 242.40M | 219.50M | 176.40M | 153.90M |
| EBITDA | 51.10M | 63.10M | 93.10M | 94.80M | 67.40M | 71.60M |
| Net Income | 13.90M | 26.00M | 50.70M | 58.60M | 38.60M | 41.80M |
Balance Sheet | ||||||
| Total Assets | 577.20M | 604.80M | 606.30M | 572.00M | 514.00M | 450.70M |
| Cash, Cash Equivalents and Short-Term Investments | 72.30M | 94.10M | 97.80M | 112.70M | 96.40M | 128.00M |
| Total Debt | 56.50M | 40.90M | 47.40M | 43.90M | 28.90M | 37.90M |
| Total Liabilities | 225.90M | 228.70M | 240.60M | 228.00M | 197.60M | 184.50M |
| Stockholders Equity | 351.30M | 376.10M | 365.70M | 344.00M | 316.40M | 266.20M |
Cash Flow | ||||||
| Free Cash Flow | 49.50M | 33.20M | 14.70M | 34.70M | 34.50M | 36.70M |
| Operating Cash Flow | 58.90M | 49.10M | 42.40M | 67.60M | 49.20M | 41.80M |
| Investing Cash Flow | -6.10M | -27.40M | -37.50M | -37.50M | -45.70M | -4.90M |
| Financing Cash Flow | -43.80M | -18.40M | -18.00M | -16.60M | -15.70M | -30.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £1.47B | 22.29 | 4.64% | 1.09% | -5.39% | -73.52% | |
72 Outperform | £2.94B | 17.58 | 9.15% | 2.12% | 3.15% | -13.57% | |
69 Neutral | £285.07M | 31.22 | 12.24% | 1.89% | 5.46% | -26.44% | |
65 Neutral | £208.02M | 25.56 | 3.13% | 2.19% | 10.66% | 21.19% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | £208.69M | -4.83 | -31.42% | ― | -16.33% | -448.12% |
Oxford Instruments has confirmed that, as of 27 February 2026, its issued share capital with voting rights comprises 55,861,331 ordinary shares of 5 pence each. The company holds no shares in treasury, meaning all issued shares carry voting rights for investors.
The disclosure provides shareholders and market participants with the denominator needed to calculate their percentage holdings under the FCA’s transparency rules. This update supports accurate reporting of significant shareholdings and enhances regulatory compliance and visibility of ownership in the company’s stock.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2970.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has extended its share buyback programme, authorising the repurchase of up to an additional £50 million of ordinary shares by no later than 2 March 2027, primarily with the aim of reducing its share capital. While most of the stock acquired will be cancelled, the company may allocate some shares to treasury for use in employee share option plans, highlighting an ongoing commitment both to capital return and to incentivising staff.
The programme will be executed under existing and future shareholder authorities, with J.P. Morgan Securities managing purchases as riskless principal within strict regulatory and market abuse rules across the London Stock Exchange and other venues. The extension, covering up to 3,735,869 shares under the current authority, signals continued confidence in the company’s valuation and cash generation, and may support earnings per share and bolster Oxford Instruments’ market positioning in the eyes of investors.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2970.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has continued executing its previously announced share buyback programme, repurchasing 10,000 ordinary shares on 12 February 2026 through Deutsche Bank’s London branch for cancellation at an average price of 2,598.9725 pence. Following this transaction, the company’s share capital will consist of 55,912,226 ordinary shares in issue, with no shares held in treasury.
The reduction in shares outstanding marginally increases existing shareholders’ relative ownership and may enhance earnings per share over time, underlining management’s ongoing use of capital return as part of its financial strategy. The updated voting rights figure also provides a new reference point for investors assessing disclosure thresholds under U.K. market transparency rules.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2891.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments plc has confirmed that, as of 30 January 2026, its issued share capital with voting rights comprises 56,015,817 ordinary shares of 5 pence each, with no shares held in treasury. The company stated that this total share figure should be used by investors as the reference denominator for determining whether they must report new or changed holdings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, clarifying the basis for regulatory threshold calculations for shareholders and market participants.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2829.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has repurchased 10,000 of its own 5p ordinary shares on 30 January 2026 under its ongoing share buyback programme, paying an average price of 2,519.9460 pence per share through Deutsche Bank’s London branch for cancellation. Following the cancellation of these shares, the company’s total shares in issue and voting rights have been reduced to 56,013,317, a move that marginally enhances earnings per share and may signal continued confidence in the company’s valuation while providing updated capital structure information for shareholders’ disclosure calculations under UK transparency rules.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2829.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments said trading for the three months to 31 December 2025 keeps the group on course to meet full‑year market expectations for adjusted operating profit, supported by a year‑to‑date book‑to‑bill ratio of 1.2 and ongoing order growth across its divisions. Imaging and Analysis orders rose 2.4% on an organic constant currency basis versus the prior year’s third quarter, with earlier restructuring in its Belfast imaging operations now delivering expected second‑half benefits, while Advanced Technologies continued to post strong momentum, with year‑to‑date orders up 44.5% and an order book stretching well into fiscal 2027. The group completed the sale of its NanoScience business on 2 January 2026, generating £48.5m in net cash, has effectively de‑risked its defined benefit pension through a buy‑in that will end company contributions after FY26, and is progressing a £100m share buyback, of which £41.2m of the first £50m tranche was completed by year‑end, even as currency headwinds are still expected to trim about £5.5m from FY26 adjusted operating profit compared with the prior year.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2430.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has confirmed that as of 31 December 2026 its issued share capital with voting rights comprises 56,154,149 ordinary shares of 5 pence each, with no shares held in treasury. The updated share capital figure provides the official denominator for investors and other stakeholders to calculate and report their notifiable holdings or changes in ownership under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, reinforcing transparency in the company’s shareholder base and compliance with regulatory reporting standards.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2430.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has disclosed share transactions by chief executive officer and person discharging managerial responsibilities (PDMR) Richard Tyson, following the exercise of a 2021 Long Term Incentive Plan (LTIP) award. Tyson exercised rights over 13,521 ordinary shares, sold 7,115 shares at £20.70 each to cover tax and fees, and transferred 14,594 shares to his spouse at nil cost, with transactions executed on 18 and 23 December 2025 on the London Stock Exchange. The disclosure, made under UK Market Abuse Regulation requirements, provides transparency around executive equity remuneration and resulting changes in the CEO’s beneficial interest, information of relevance to shareholders monitoring insider dealings and alignment of management incentives with investor interests.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2430.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.
Oxford Instruments has executed a share buyback program, purchasing 13,195 of its ordinary shares at an average price of 2048.6976 pence per share for cancellation. This move reduces the total number of shares in issue to 56,169,937, potentially increasing the value of remaining shares and reflecting the company’s confidence in its market position.
The most recent analyst rating on (GB:OXIG) stock is a Buy with a £2430.00 price target. To see the full list of analyst forecasts on Oxford Instruments stock, see the GB:OXIG Stock Forecast page.